View in EDS

Safety of BNT162b2 mRNA vaccine booster in the setting of Ad26.COV2.S-associated VITT.

Saved in:
Bibliographic Details
Title: Safety of BNT162b2 mRNA vaccine booster in the setting of Ad26.COV2.S-associated VITT.
Authors: Abou-Ismail MY; Division of Hematology and Hematologic Malignancies, Department of Internal Medicine, University of Utah Health Sciences Center, Salt Lake City, UT., Kanack AJ; Division of Experimental Pathology, Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN., Splinter NP; Division of Experimental Pathology, Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN., Smock KJ; Department of Pathology, University of Utah Health Sciences Center, Salt Lake City, UT.; Associated Regional and University Pathologists Institute for Clinical and Experimental Pathology®, Salt Lake City, UT; and., Moser KA; Department of Pathology, University of Utah Health Sciences Center, Salt Lake City, UT.; Associated Regional and University Pathologists Institute for Clinical and Experimental Pathology®, Salt Lake City, UT; and., Padmanabhan A; Divisions of Hematopathology, Transfusion Medicine, & Experimental Pathology, Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN.
Source: Blood advances [Blood Adv] 2022 Sep 27; Vol. 6 (18), pp. 5327-5329.
Publication Type: Journal Article; Research Support, N.I.H., Extramural
Journal Info: Publisher: American Society of Hematology Country of Publication: United States NLM ID: 101698425 Publication Model: Print Cited Medium: Internet ISSN: 2473-9537 (Electronic) Linking ISSN: 24739529 NLM ISO Abbreviation: Blood Adv Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:2473-9537
DOI:10.1182/bloodadvances.2022007753